Kindred Biosciences, Inc. (NASDAQ:KIN) was the recipient of a large drop in short interest during the month of July. As of July 31st, there was short interest totalling 714,173 shares, a drop of 29.0% from the July 14th total of 1,005,956 shares. Currently, 2.8% of the company’s shares are sold short. Based on an average daily trading volume, of 242,575 shares, the days-to-cover ratio is presently 2.9 days.

Several equities research analysts recently weighed in on the company. FBR & Co assumed coverage on Kindred Biosciences in a research report on Wednesday, May 24th. They set an “outperform” rating and a $10.00 price target on the stock. Zacks Investment Research upgraded Kindred Biosciences from a “hold” rating to a “buy” rating and set a $7.50 price target on the stock in a research report on Friday, June 2nd. Aegis assumed coverage on Kindred Biosciences in a research report on Friday, June 16th. They set a “buy” rating and a $10.50 price target on the stock. ValuEngine upgraded Kindred Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, BMO Capital Markets restated a “hold” rating and set a $8.00 price target on shares of Kindred Biosciences in a research report on Monday, May 15th. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $8.85.

Shares of Kindred Biosciences (NASDAQ:KIN) opened at 7.10 on Monday. Kindred Biosciences has a 52-week low of $3.90 and a 52-week high of $9.65. The company’s market capitalization is $197.64 million. The company’s 50 day moving average price is $7.83 and its 200 day moving average price is $7.00.

Kindred Biosciences (NASDAQ:KIN) last issued its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.04. On average, analysts predict that Kindred Biosciences will post ($1.27) EPS for the current year.

In other news, insider Richard Chin sold 13,000 shares of Kindred Biosciences stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $7.75, for a total value of $100,750.00. Following the sale, the insider now directly owns 2,310,546 shares in the company, valued at approximately $17,906,731.50. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Park West Asset Management Llc acquired 600,000 shares of the business’s stock in a transaction dated Wednesday, July 12th. The stock was acquired at an average price of $7.50 per share, for a total transaction of $4,500,000.00. The disclosure for this purchase can be found here. 19.10% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of KIN. Nationwide Fund Advisors acquired a new stake in shares of Kindred Biosciences during the second quarter valued at approximately $100,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Kindred Biosciences during the first quarter valued at approximately $102,000. JPMorgan Chase & Co. acquired a new stake in shares of Kindred Biosciences during the second quarter valued at approximately $119,000. Trexquant Investment LP acquired a new stake in shares of Kindred Biosciences during the second quarter valued at approximately $120,000. Finally, OxFORD Asset Management LLP acquired a new stake in shares of Kindred Biosciences during the second quarter valued at approximately $128,000. Hedge funds and other institutional investors own 51.91% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/14/kindred-biosciences-inc-kin-short-interest-down-29-0-in-july.html.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Receive News & Ratings for Kindred Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.